High dose Bortezomib plus second line chemo-therapy in treatment of patients with fractory and relapsed diffuse large B cell lymphoma.
Phase of Trial: Phase II
Latest Information Update: 22 Apr 2016
At a glance
- Drugs Bortezomib (Primary) ; Antineoplastics
- Indications Diffuse large B cell lymphoma
- Focus Adverse reactions; Therapeutic Use
- 21 May 2012 Planned end date changed from 1 Dec 2012 to 31 Dec 2013 as reported by Chinese Clinical Trial Register.
- 08 Jul 2010 New trial record